Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer

Molecular Oncology

Volumn 8, Issue 7, 2014, Pages 1326-1338

  Abdel Fatah, Tarek M A ^a   Russell, Roslin ^b,c   Albarakati, Nada ^d   Maloney, David J ^e   Dorjsuren, Dorjbal ^e   Rueda, Oscar M ^b,c   Moseley, Paul ^a   Mohan, Vivek ^d   Sun, Hongmao ^e   Abbotts, Rachel ^d   Mukherjee, Abhik ^d   Agarwal, Devika ^f   Illuzzi, Jennifer L ^e   Jadhav, Ajit ^e   Simeonov, Anton ^e   Ball, Graham ^f   Chan, Stephen ^a   Caldas, Carlos ^b,c   Ellis, Ian O ^f   Wilson, David M ^e   Madhusudan, Srinivasan ^a,d   more..

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Drug target; FEN1; Predictive factor; Prognostic factor

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLAP ENDONUCLEASE; FLAP ENDONUCLEASE 1; MESSENGER RNA; UNCLASSIFIED DRUG; FEN1 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MITOSIS INDEX; MULTIVARIATE ANALYSIS; OVARY CANCER; OVARY CARCINOMA; PHENOTYPE; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; UNIVARIATE ANALYSIS; BREAST; BREAST NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; PROGNOSIS;

AGED; BIOMARKERS, TUMOR; BREAST; BREAST NEOPLASMS; FEMALE; FLAP ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROGNOSIS;

EID: 84908547511     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.04.009     Document Type: Article

References (39)

1. Abdel-Fatah T., Arora A., Gorguc I., Abbotts R., Beebeejaun S., Storr S., Mohan V., Hawkes C., Soomro I., Lobo D.N., Parsons S.L., Madhusudan S. Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer?. Antioxid. Redox Signal 2013, 18:2392-2398.
2. Abdel-Fatah T.M., Albarakati N., Bowell L., Agarwal D., Moseley P., Hawkes C., Ball G., Chan S., Ellis I.O., Madhusudan S. Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. Breast Cancer Res. Treat. 2013, 142:515-527.
3. Abdel-Fatah T.M., Perry C., Dickinson P., Ball G., Moseley P., Madhusudan S., Ellis I.O., Chan S.Y. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC7) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann. Oncol. 2013, 24:2801-2807.
4. Abdel-Fatah T.M., Perry C., Moseley P., Johnson K., Arora A., Chan S., Ellis I.O., Madhusudan S. Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer. Breast Cancer Res. Treat. 2014, 143:411-421.
5. Abdel-Fatah T.M., Russell R., Agarwal D., Moseley P., Abayomi M.A., Perry C., Albarakati N., Ball G., Chan S., Caldas C., Ellis I.O., Madhusudan S. DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol. Oncol. 2014, S1574-7891, 00002-00007.
6. Bergh J., Norberg T., Sjogren S., Lindgren A., Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med. 1995, 1:1029-1034.
7. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3:323-327.
8. Buterin T., Koch C., Naegeli H. Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis 2006, 27:1567-1578.
9. Chin S.F., Teschendorff A.E., Marioni J.C., Wang Y., Barbosa-Morais N.L., Thorne N.P., Costa J.L., Pinder S.E., van de Wiel M.A., Green A.R., Ellis I.O., Porter P.L., Tavare S., Brenton J.D., Ylstra B., Caldas C. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 2007, 8:R215.
10. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., Graf S., Ha G., Haffari G., Bashashati A., Russell R., McKinney S., Langerod A., Green A., Provenzano E., Wishart G., Pinder S., Watson P., Markowetz F., Murphy L., Ellis I., Purushotham A., Borresen-Dale A.L., Brenton J.D., Tavare S., Caldas C., Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
11. Dorjsuren D., Kim D., Maloney D.J., Wilson D.M., Simeonov A. Complementary non-radioactive assays for investigation of human flap endonuclease 1 activity. Nucleic Acids Res. 2011, 39:e11.
12. Guo X., Yang C., Qian X., Lei T., Li Y., Shen H., Fu L., Xu B. Estrogen receptor α regulates ATM Expression through miRNAs in breast cancer. Clin Cancer Res 2013, 19:4994-5002.
13. Henneke G., Friedrich-Heineken E., Hubscher U. Flap endonuclease 1: a novel tumour suppresser protein. Trends Biochem. Sci. 2003, 28:384-390.
14. Henneke G., Koundrioukoff S., Hubscher U. Phosphorylation of human Fen1 by cyclin-dependent kinase modulates its role in replication fork regulation. Oncogene 2003, 22:4301-4313.
15. Hothorn T., Hornik K., Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J.Comput. Graph Stat. 2006, 15:651-674.
16. Kim I.S. Down-regulation of human FEN-1 gene expression during differentiation of promyelocytic leukemia cells. Exp. Mol. Med. 1998, 30:252-256.
17. Kim J.M., Sohn H.Y., Yoon S.Y., Oh J.H., Yang J.O., Kim J.H., Song K.S., Rho S.M., Yoo H.S., Kim Y.S., Kim J.G., Kim N.S. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin. Cancer Res. 2005, 11:473-482.
18. Krause A., Combaret V., Iacono I., Lacroix B., Compagnon C., Bergeron C., Valsesia-Wittmann S., Leissner P., Mougin B., Puisieux A. Genome-wide analysis of gene expression in neuroblastomas detected by mass screening. Cancer Lett. 2005, 225:111-120.
19. Kucherlapati M., Nguyen A., Kuraguchi M., Yang K., Fan K., Bronson R., Wei K., Lipkin M., Edelmann W., Kucherlapati R. Tumor progression in Apc(1638N) mice with Exo1 and Fen1 deficiencies. Oncogene 2007, 26:6297-6306.
20. Kucherlapati M., Yang K., Kuraguchi M., Zhao J., Lia M., Heyer J., Kane M.F., Fan K., Russell R., Brown A.M., Kneitz B., Edelmann W., Kolodner R.D., Lipkin M., Kucherlapati R. Haploinsufficiency of flap endonuclease (Fen1) leads to rapid tumor progression. Proc. Natl. Acad. Sci. U. S. A 2002, 99:9924-9929.
21. Lam J.S., Seligson D.B., Yu H., Li A., Eeva M., Pantuck A.J., Zeng G., Horvath S., Belldegrun A.S. Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int. 2006, 98:445-451.
22. Larsen E., Gran C., Saether B.E., Seeberg E., Klungland A. Proliferation failure and gamma radiation sensitivity of Fen1 null mutant mice at the blastocyst stage. Mol. Cell Biol. 2003, 23:5346-5353.
23. Larsen E., Kleppa L., Meza T.J., Meza-Zepeda L.A., Rada C., Castellanos C.G., Lien G.F., Nesse G.J., Neuberger M.S., Laerdahl J.K., William Doughty R., Klungland A. Early-onset lymphoma and extensive embryonic apoptosis in two domain-specific Fen1 mice mutants. Cancer Res. 2008, 68:4571-4579.
24. Liu L., Zhou C., Zhou L., Peng L., Li D., Zhang X., Zhou M., Kuang P., Yuan Q., Song X., Yang M. Functional FEN1 genetic variants contribute to risk of hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer. Carcinogenesis 2012, 33:119-123.
25. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J.Natl. Cancer Inst. 2005, 97:1180-1184.
26. Moggs J.G., Murphy T.C., Lim F.L., Moore D.J., Stuckey R., Antrobus K., Kimber I., Orphanides G. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. J.Mol. Endocrinol. 2005, 34:535-551.
27. Nikolova T., Christmann M., Kaina B. FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res. 2009, 29:2453-2459.
28. Pawitan Y., Bjohle J., Amler L., Borg A.L., Egyhazi S., Hall P., Han X., Holmberg L., Huang F., Klaar S., Liu E.T., Miller L., Nordgren H., Ploner A., Sandelin K., Shaw P.M., Smeds J., Skoog L., Wedren S., Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005, 7:R953-R964.
29. Sato M., Girard L., Sekine I., Sunaga N., Ramirez R.D., Kamibayashi C., Minna J.D. Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer. Oncogene 2003, 22:7243-7246.
30. Schultz-Norton J.R., Walt K.A., Ziegler Y.S., McLeod I.X., Yates J.R., Raetzman L.T., Nardulli A.M. The deoxyribonucleic acid repair protein flap endonuclease-1 modulates estrogen-responsive gene expression. Mol Endocrinol 2007, 21:1569-1580.
31. Shen B., Singh P., Liu R., Qiu J., Zheng L., Finger L.D., Alas S. Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases. Bioessays 2005, 27:717-729.
32. Singh P., Yang M., Dai H., Yu D., Huang Q., Tan W., Kernstine K.H., Lin D., Shen B. Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers. Mol. Cancer Res. 2008, 6:1710-1717.
33. Sultana R., Abdel-Fatah T., Abbotts R., Hawkes C., Albarakati N., Seedhouse C., Ball G., Chan S., Rakha E.A., Ellis I.O., Madhusudan S. Targeting XRCC1 deficiency in breast cancer for personalized therapy. Cancer Res. 2013, 73:1621-1634.
34. van Pel D.M., Barrett I.J., Shimizu Y., Sajesh B.V., Guppy B.J., Pfeifer T., McManus K.J., Hieter P. An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet. 2013, 9:e1003254.
35. Wu Z., Lin Y., Xu H., Dai H., Zhou M., Tsao S., Zheng L., Shen B. High risk of benzo[alpha]pyrene-induced lung cancer in E160D FEN1 mutant mice. Mutat. Res. 2012, 731:85-91.
36. Xu H., Zheng L., Dai H., Zhou M., Hua Y., Shen B. Chemical-induced cancer incidence and underlying mechanisms in Fen1 mutant mice. Oncogene 2011, 30:1072-1081.
37. Yang M., Guo H., Wu C., He Y., Yu D., Zhou L., Wang F., Xu J., Tan W., Wang G., Shen B., Yuan J., Wu T., Lin D. Functional FEN1 polymorphisms are associated with DNA damage levels and lung cancer risk. Hum. Mutat. 2009, 30:1320-1328.
38. Zheng L., Dai H., Zhou M., Li M., Singh P., Qiu J., Tsark W., Huang Q., Kernstine K., Zhang X., Lin D., Shen B. Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat. Med. 2007, 13:812-819.
39. Zheng L., Jia J., Finger L.D., Guo Z., Zer C., Shen B. Functional regulation of FEN1 nuclease and its link to cancer. Nucleic Acids Res. 2011, 39:781-794.